Stifel Nicolaus Lowers Alto Neuroscience (NYSE:ANRO) Price Target to $10.00

Alto Neuroscience (NYSE:ANRO) had its price target lowered by Stifel Nicolaus from $32.00 to $10.00 in a research note published on Wednesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other analysts also recently weighed in on ANRO. RODMAN&RENSHAW downgraded shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Wedbush downgraded shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $29.00 to $4.00 in a research report on Wednesday, October 23rd. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Finally, Robert W. Baird reduced their price objective on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Alto Neuroscience Stock Performance

Shares of NYSE:ANRO opened at $4.52 on Wednesday. The company has a quick ratio of 19.85, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 52-week low of $3.61 and a 52-week high of $24.00. The company has a 50 day moving average of $9.86 and a two-hundred day moving average of $11.41.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. Sell-side analysts predict that Alto Neuroscience will post -2.63 EPS for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. bought a new stake in Alto Neuroscience in the first quarter valued at $8,233,000. Price T Rowe Associates Inc. MD bought a new stake in Alto Neuroscience in the first quarter valued at $9,788,000. AWM Investment Company Inc. bought a new stake in Alto Neuroscience in the first quarter valued at $4,592,000. Zimmer Partners LP bought a new stake in Alto Neuroscience in the first quarter valued at $1,151,000. Finally, Artal Group S.A. acquired a new position in shares of Alto Neuroscience during the first quarter valued at $5,372,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.